A pathophysiological paradigm for the therapy of psychiatric disease

Nature Reviews Drug Discovery

Volumn 4, Issue 6, 2005, Pages 467-476

  Spedding, Michael ^a   Jay, Thérèse ^c   Costa e Silva, Jorge ^d   Perret, Laurent ^b  

^a IRIS Institut de Recherches Internationales Servier   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c INSERM   (France)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NEUROTROPHIN; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE;

ANXIETY; BODY WEIGHT DISORDER; BRAIN DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; GENE SEQUENCE; HUMAN; MENTAL DISEASE; MENTAL STRESS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL BEHAVIOR; WEIGHT GAIN;

ANIMALS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 20844449415     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1753     Document Type: Review

References (94)

1. Wong, M. L. & Licinio, J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nature Rev. Drug Discov. 3, 136-151 (2004).
2. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353-359 (2004).
3. Mayberg, H. S. Limbic-cortical dysregulation: a proposed model of depression. J. Neuropsychiatry Clin. Neurosci. 9, 471-481 (1997).
4. Goldapple, K. et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch. Gen. Psychiatry 61, 34-41 (2004).
5. Keightley, M. L. et al. Personality influences limbic-cortical interactions during sad mood induction. Neuroimage 20, 2031-2039 (2003).
6. Mayberg, H. S., Lewis, P. J., Regenold, W. & Wagner, H. N. Jr. Paralimbic hypoperfusion in unipolar depression. J. Nucl. Med. 35, 929-934 (1994).
7. Seminowicz, D. A. et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 22, 409-418 (2004).
8. Mayberg, H. S. et al. Deep brain stimulation for treatment-resistant depression. Neuron 45, 651-660 (2005).
9. Manji, H. K. et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53, 707-742 (2003).
10. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
11. Shorter, E. & Tyrer, P. Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease. BMJ 327, 158-160 (2003).
12. Caspi, A. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389 (2003).
13. Ekselius, L. & Von Knorring, L. Changes in personality traits during treatment with sertraline or citalopram. Br. J. Psychiatry 174, 444-448 (1999).
14. Edwards, J. G. Suicide and antidepressants. BMJ 310, 205-206 (1995).
15. Healy, D., Langmaak, C. & Savage, M. Suicide in the course of the treatment of depression. J. Psychopharmacol. 13, 94-99 (1999).
16. Michael, A. & O'Keane, V. Sexual dysfunction in depression. Hum. Psychopharmacol. 15, 337-345 (2000).
17. Henderson, D. C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16, 77-89 (2002).
18. Meltzer, H. Y. Introduction: cardiovascular and metabolic risks associated with schizophrenia and antipsychotic drug treatment. J. Clin. Psychiatry 63, 3-4 (2002).
19. Davidson, M. Risk of cardiovascular disease and sudden death in schizophrenia. J. Clin. Psychiatry 63 (Suppl. 9), 5-11 (2002).
20. Vieweg, W. V. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J. Clin. Psychiatry 63 (Suppl. 9), 18-24 (2002).
21. Zhang, X. et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (in the press).
22. Pezawas, L. et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci. 24, 10099-10102 (2004).
23. Francis, D. D., Szegda, K., Campbell, G., Martin, W. D. & Insel, T. R. Epigenetic sources of behavioral differences in mice. Nature Neurosci. 6, 445-446 (2003).
24. Rutter, M. L. Psychosocial adversity and child psychopathology. Br. J. Psychiatry 174, 480-493 (1999).
25. Kendler, K. S. et al. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. Arch. Gen. Psychiatry 57, 953-959 (2000).
26. Andriamampandry, C. et al. Mss4 gene is up-regulated in rat brain after chronic treatment with antidepressant and down-regulated when rats are anhedonic. Mol. Pharmacol. 62, 1332-1338 (2002).
27. Gunther, E. C., Stone, D. J., Gerwien, R. W., Bento, P. & Heyes, M. P. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl Acad. Sci. USA 100, 9608-9613 (2003).
28. Moller, H. J. Anxiety associated with comorbid depression. J. Clin. Psychiatry 63 (Suppl. 14), 22-26 (2002).
29. Rogan, M. T., Staubli, U. V. & LeDoux, J. E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390, 604-607 (1997).
30. McKernan, M. G. & Shinnick-Gallagher, P. Fear conditioning induces a lasting potentiation of synaptic currents in vitro. Nature 390, 607-611 (1997).
31. Convit, A. et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol. Aging 18, 131-138 (1997).
32. Golomb, J. et al. Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Learn. Mem. 1, 45-54 (1994).
33. Bremner, J. D. et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am. J. Psychiatry 152, 973-981 (1995).
34. Gurvits, T. V. et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related posttraumatic stress disorder. Biol. Psychiatry 40, 1091-1099 (1996).
35. Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G. & Vannier, M. W. Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sci. USA 93, 3908-3913 (1996).
36. Sheline, Y. I., Sanghavi, M., Mintun, M. A. & Gado, M. H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 19, 5034-5043 (1999).
37. Duman, R. S. & Charney D. S. Cell atrophy and loss in major depression. Biol. Psychiatry 45, 1083-1084 (1999).
38. Kim, J. J. & Diamond, D. M. The stressed hippocampus, synaptic plasticity and lost memories. Nature Rev. Neurosci. 3, 453-462 (2002).
39. Rocher, C., Spedding, M., Munoz, C. & Jay, T. M. Acute Stress-induced Changes in Hippocampal/Prefrontal Circuits in Rats: Effects of Antidepressants. Cereb. Cortex 14, 224-229 (2004).
40. Meaney, M. J., Aitken, D. H., van Berkel, C., Bhatnagar, S. & Sapolsky, R. M. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science 239, 766-768 (1988).
41. Kofman, O. The role of prenatal stress in the etiology of developmental behavioural disorders. Neurosci. Biobehav. Rev. 26, 457-470 (2002).
42. Vythilingam, M. et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am. J. Psychiatry 159, 2072-2080 (2002).
43. Nakano, T. et al. Relationship between distressing cancer-related recollections and hippocampal volume in cancer survivors. Am. J. Psychiatry 159, 2087-2093 (2002).
44. Pham, K., McEwen, B. S., LeDoux, J. E. & Nader, K. Fear learning transiently impairs hippocampal cell proliferation. Neuroscience 130, 17-24 (2005).
45. Bliss, T. V. & Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31-39 (1993).
46. Martin, S. J., Grimwood, P. D. & Morris, R. G. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 23, 649-711 (2000).
47. Nagerl, U. V., Eberhorn, N., Cambridge, S. B. & Bonhoeffer, T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron 44, 759-767 (2004).
48. Zhou, Q., Homma, K. J. & Poo, M. M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 44, 749-757 (2004).
49. Rioult-Pedotti, M. S., Friedman, D. & Donoghue, J. P. Learning-induced LTP in neocortex. Science 290, 533-536 (2000).
50. Knott, G. W., Quairiaux, C., Genoud, C. & Welker, E. Formation of dendritic spines with GABAergic synapses induced by whisker stimulation in adult mice. Neuron 34, 265-273 (2002).
51. Marrone, D. F. & Petit, T. L. The role of synaptic morphology in neural plasticity: structural interactions underlying synaptic power. Brain Res. Brain Res. Rev. 38, 291-308 (2002).
52. Kempermann, G., Gast, D. & Gage, F. H. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann. Neurol. 52, 135-143 (2002).
53. Pluchino, S. et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422, 688-694 (2003).
54. Mezey, E. et al. Transplanted bone marrow generates new neurons in human brains. Proc. Natl Acad. Sci. USA 100, 1364-1369 (2003).
55. Spedding, M., Neau, I. & Horsing, L. Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy. Curr. Opin. Pharmacol. 3, 33-40 (2003).
56. Sochi, M. S. & Sanders-Bush, E. Serotonin and brain development. Int. Rev. Neurobiol. 59, 111-174 (2004).
57. West, A. R., Floresco, S. B., Charara, A., Rosenkranz, J. A. &Grace, A. A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann. NY Acad. Sci. 1003, 53-74 (2003).
58. Gurden, H., Takita, M. & Jay, T. M. Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J. Neurosci. 20, RC106 (2000).
59. Schultz, W., Tremblay, L. & Hollerman, J. R. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb. Cortex 10, 272-284 (2000).
60. Duman, R. S., Heninger, G. R. & Nestler, E. J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597-606 (1997).
61. Skolnick, P. Antidepressants for the new millennium. Eur. J. Pharmacol. 375, 31-40 (1999).
62. Tongiorgi, E., Righi, M. & Cattaneo, A. Activity-dependent dendritic targeting of BDNF and TrkB mRNAs in hippocampal neurons. J. Neurosci. 17, 9492-9505 (1997).
63. Kafitz, K. W., Rose, C. R., Thoenen, H. & Konnerth, A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 401, 918-921 (1999).
64. Kovalchuk, Y., Hanse, E., Kafitz, K. W. & Konnerth, A. Postsynaptic Induction of BDNF-Mediated Long-Term Potentiation. Science 295, 1729-1734 (2002).
65. Suzuki, F., Junior, M. P., Guilhem, D., Sorensen, J. C. & Onteniente, B. Morphogenetic effect of kainate on adult hippocampal neurons associated with a prolonged expression of brain-derived neurotrophic factor. Neuroscience 64, 665-674 (1995).
66. Cohen-Cory, S. BDNF modulates, but does not mediate, activity-dependent branching and remodeling of optic axon arbors in vivo. J. Neurosci. 19, 9996-10003 (1999).
67. Young, D., Lawlor, P. A., Leone, P., Dragunow, M. & During, M. J. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nature Med. 5, 448-453 (1999).
68. Berchtold, N. C., Kesslak, J. P., Pike, C. J., Adlard, P. A. & Cotman, C. W. Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur J. Neurosci. 14, 1992-2002 (2001).
69. Russo-Neustadt, A., Beard, R. C. & Cotman, C. W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21, 679-682 (1999).
70. Lauterborn, J. C., Poulsen, F. R., Stinis, C. T., Isackson, P. J. & Gall, C. M. Transcript-specific effects of adrenalectomy on seizure-induced BDNF expression in rat hippocampus. Brain Res. Mol. Brain Res. 55, 81-91 (1998).
71. Lauterborn, J. C., Lynch, G., Vanderklish, P., Arai, A. & Gall, C. M. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20, 8-21 (2000).
72. Dicou, E., Rangon, C. M., Guimiot, F., Spedding, M. & Gressens, P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res. 970, 221-225 (2003).
73. Spedding, M., Sebban, C. & Perrot, L. New directions for drug discovery in psychiatric disease. Dialogues Clin. Neurosci. 4, 336-341 (2002).
74. Krystal, J. H. et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169, 215-233 (2003).
75. Bremner, J. D. et al. Reduced volume of orbitofrontal cortex in major depression. Biol. Psychiatry 51, 273-279 (2002).
76. Campbell, S., Marriott, M., Nahmias, C. & MacQueen, G. M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 161, 598-607 (2004).
77. Shakesby A. C., Anwyl, R. & Rowan, M. J. Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J. Neurosci. 22, 3638-3644 (2002).
78. Czeh, B. et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl Acad. Sci. USA 98, 12796-12801 (2001).
79. File, S. E., Zangrossi, H., Jr., Viana, M. & Graeff, F. G. Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology (Berl) 111, 491-494 (1993).
80. Haller, J. & Halasz, J. Effects of two acute stressors on the anxiolytic efficacy of chlordiazepoxide. Psychopharmacology (Berl) 151, 1-6 (2000).
81. Kent, J. M., Mathew, S. J. & Gorman, J. M. Molecular targets in the treatment of anxiety. Biol. Psychiatry 52, 1008-1030 (2002).
82. Weinberger, D. R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987).
83. Kalus, P., Senitz, D., Lauer, M. & Beckmann, H. Inhibitory cartridge synapses in the anterior cingulate cortex of schizophrenics. J. Neural. Transm. 106, 763-771 (1999).
84. Beckmann, H. Developmental malformations in cerebral structures of schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4), 44-47 (1999).
85. Gur, R. C., Gunning-Dixon, F., Bilker, W. B. & Gur, R. E. Sex differences in temporo-limbic and frontal brain volumes of healthy adults. Cereb. Cortex 12, 998-1003 (2002).
86. Andreasen, N. C. et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry 49, 943-958 (1992).
87. Harrison, P. J. The neuropathological effects of antipsychotic drugs. Schizophr. Res. 40, 87-99 (1999).
88. Gogtay, N., Giedd, J. & Rapoport, J. L. Brain development in healthy, hyperactive, and psychotic children. Arch. Neurol. 59, 1244-1248 (2002).
89. Tamminga, C. A. & Medoff, D. R. Studies in schizophrenia: pathophysiology and treatment. Dialogues Clin. Neurosci. 4, 432-437 (2002).
90. Yamasaki, H., LaBar, K. S. & McCarthy, G. Dissociable prefrontal brain systems for attention and emotion. Proc. Natl Acad. Sci. USA 99, 11447-11451 (2002).
91. 2A-receptors. Br. J. Pharmacol. 135, 65-78 (2002).
92. Burghardt, N. S., Sullivan, G. M., McEwen, B. S., Gorman, J. M. & LeDoux, J. E. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol. Psychiatry 55, 1171-1178 (2004).
93. McEwen, B. S., Magarinos, A. M. & Reagan, L. P. Structural plasticity and tianeptine: cellular and molecular targets. Eur. Psychiatry 17 (Suppl. 3), 318-330 (2002).
94. Radley, J. J. et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 125, 1-6 (2004).